Puma Biotechnology Inc Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (37)

Latest Posts

About This Stock More About This Stock
Stock Charts To Watch - Monday, December 2
Video By: Harry Boxer
Monday, December 2, 2019 9:51 PM EDT
Clovis Oncology, Inc. was up 1.50, or 10%, to 16.43, with a high of 17.37, on 40 million shares on Monday. This stock has been a monster.
In this video: X, CLVS, BYND, PBYI, WWE, TWLO
Research Report: PBYI
Article By: Elle Investments
Friday, May 24, 2019 1:41 PM EDT
The lowered 2019 Nerlynx net sales guidance after 1Q19 results puts previous peak sales estimates of $1B+ in doubt. However, given the large sell-off, even with much lower peak sales estimates in the $500M+ range, there is still a lot of upside.
In this article: PBYI
Puma Biotechnology: A Favorable Risk/Reward Bet
Article By: Elle Investments
Thursday, April 11, 2019 2:31 PM EDT
PBYI dropped about 8% when the EU/Africa licensing deal with Pierre Fabre was announced for potential blockbuster candidate Nerlynx, which is currently approved in the US and EU for HER2+ breast cancer treatment (post-Herceptin).
In this article: PBYI
Puma Biotech: Is It Time For This Kitty To Roar?
Article By: TipRanks
Wednesday, October 10, 2018 10:29 PM EDT
Puma is an oncology company with drug Nerlynx approved for HER2 positive adjuvant breast cancer. But the market has yet to appreciate the drug’s full potential.
In this article: PBYI
Week In Review: C-Bridge Raising Another $650 Million For China Healthcare
Article By: ChinaBio® Today
Saturday, February 3, 2018 4:43 PM EDT
Shanghai's C-Bridge Capital is raising capital for its third healthcare private equity fund with a target of $650 million (see story). Just six months ago, C-Bridge closed its second PE fund at a hard cap of $400 million.
In this article: CASI, SRNE, PBYI

Latest Tweets for $PBYI

No tweets yet!